Title
Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients
Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
Phase
Phase 3Lead Sponsor
University of LimogesStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
CancerIntervention/Treatment
warfarin enoxaparin ...Study Participants
420This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).
Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months
Inclusion Criteria: First line chemotherapy for solid tumor with: Metastatic disease or Involved nodes or Unresectable tumor Indication for Implantable device for central venous access Potential survival > 3 months ECOG performance status 0 to 2 (WHO) Age between 18 and 75 years. Social security guaranteed Normal laboratory assessments (platelets> 100000/mm3, TP 60%, spontaneous TCA with M/T<1.5, TGO and TGP < 2xN, serum creatinin<120µmol/l) Informed consent signed Exclusion Criteria: Inability to understand informed consent or interfering with compliance for treatment or protocol Anti-coagulant treatment -related criteria Acute infectious endocarditis History related with heparin allergy or thrombopenia due to heparin Uncontrolled high blood pressure (systolic blood pressure >180 mm Hg and/or diastolic blood pressure >110 mm Hg) Hemorrhagic syndrome ongoing Patient with platelet inhibitors treatment Chronic, daily treatment with anti-coagulant therapy (LMWH or AVK), use as preventive or curative level Patient with liver failure (TP<60%) or renal insufficiency (creatinin clearance< 20 ml/mn) Women with pregnancy and lactating Pathology-related criteria deep venous thrombosis history or pulmonary embolism (< 6 months) Clinical suspicious of brain metastasis